A novel cardiometabolic therapeutic prospect Cardiometabolic diseases as diabetes mellitus, heart disease, overweight, obesity, hypertension, hyperlipidemia and its multiple macro and microvascular complications (ischemic cardiomyopathy, stroke, chronic kidney disease, retinopathy, peripheral neuropathy, etc.) are conditions closely related to each other and constitute at present time the leading cause of morbility, disability and death in the world [28]
What makes GLP-1 drugs particularly intriguing is that they appear to work through a mechanism distinct from traditional addiction treatments
Have you heard about doctor-prescribed weight loss medicines
capacity and permit generics suggests that supply may outstrip demand in several years, improving affordability
Here, we mainly summarize the relevant experiments on the SMG treatment effect in people with obesity (STEP) programs
2026 May 2;407(10540):1687-1698